Term ends Dec 8, 2027 · Medium confidence
20-year base term ended Oct 24, 2023
Why Medium: A parent in the chain could not be resolved.
Held by Vyne Therapeutics Inc.
Filed Jul 5, 2007 as application 11/825,406 · Granted Feb 23, 2016
Base term plus 1506 days of patent term adjustment (USPTO delay)
Today
2003
2027
Clock starts
Oct 24, 2003
Oct 24, 2003
Term ends
Dec 8, 2027
Dec 8, 2027
Granted
Feb 23, 2016
Feb 23, 2016
base term
patent term adjustment
fee events
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
1,506
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
82
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 1506 days past its 20-year base term on prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 24, 2003, when application PCT/IB2003/005527, the earliest non-provisional in its chain, was filed (this one was filed Jul 5, 2007); a parent in its chain could not be resolved (the next row) | Oct 24, 2023 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +1506 days, USPTO patent term adjustment record | Dec 8, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 8, 2027 | Medium confidence |
Partial family
| Application PCT/IB0300/005527 | PCT application no patent term | no patent term |
| Application PCT/IB2003/005527 | PCT application no patent term | no patent term |
| US 7,820,145 | In force Aug 2028 | Aug 2028 |
| Application 10/911,367 | Abandoned not computed | not computed |
| US 7,700,076 | In force no later than Sep 2027 | no later than Sep 2027 |
| Application 11/041,921 | Abandoned not computed | not computed |
| US 9,668,972 | Lapsed on the fee record Jun 2025 | Jun 2025 |
| Application 11/078,948 | Abandoned not computed | not computed |
8 of 82 applications in this family shown, earliest filings first. Partial: 5 of the 82 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 10, 2007 Reel 20094, frame 430 | Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David | Foamix, Ltd. | Assignment of Assignor's Interest |
| Jul 30, 2014 Reel 33445, frame 249 | Foamix Ltd. | Foamix Pharmaceuticals Ltd. | Change of Name |
| Jul 30, 2019 Reel 49912, frame 45 | Foamix Pharmaceuticals Ltd. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Nov 4, 2020 Reel 54306, frame 387 | Foamix Pharmaceuticals Ltd. | Vyne Pharmaceuticals Ltd. | Change of Name |
| Feb 4, 2021 Reel 55215, frame 298 | Vyne Pharmaceuticals Ltd. | Vyne Therapeutics Inc. | Assignment of Assignor's Interest |
| Feb 17, 2021 Reel 55326, frame 9 | Vyne Therapeutics Inc. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Sep 20, 2021 Reel 57544, frame 138 | Perceptive Credit Holdings II, LP | Vyne Pharmaceuticals Ltd. (F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Sep 20, 2021 Reel 57544, frame 708 | Perceptive Credit Holdings II, LP | Vyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2027
Term ends Dec 8, 2027. No further fees fall due before then
Note
The 1506 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
220
later US patents cite this one
That is top 1% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.